1. Home
  2. RVYL vs GTBP Comparison

RVYL vs GTBP Comparison

Compare RVYL & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RVYL

Ryvyl Inc.

HOLD

Current Price

$7.81

Market Cap

8.5M

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.39

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVYL
GTBP
Founded
2007
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
8.8M
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
RVYL
GTBP
Price
$7.81
$0.39
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.2K
1.3M
Earning Date
04-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
$11,131,000.00
N/A
Revenue This Year
$770.54
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.26
52 Week High
$8.55
$3.73

Technical Indicators

Market Signals
Indicator
RVYL
GTBP
Relative Strength Index (RSI) 67.46 51.65
Support Level $5.00 $0.26
Resistance Level $8.55 $0.44
Average True Range (ATR) 0.65 0.04
MACD 0.11 0.01
Stochastic Oscillator 96.06 55.53

Price Performance

Historical Comparison
RVYL
GTBP

About RVYL Ryvyl Inc.

Ryvyl Inc is a financial technology company that provides payment acceptance and disbursement solutions, mainly enabling merchants to process credit card transactions through BIN sponsorship arrangements with acquiring banks and payment processors, where it operates as an intermediary performing functions such as merchant underwriting, onboarding, risk monitoring, and customer support. The company also offers its internally developed NEMS Core platform, which facilitates automated inbound and outbound disbursements through a modular workflow system.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: